|1.||Gualberto, Antonio: 7 articles (12/2011 - 07/2009)|
|2.||Yin, Donghua: 5 articles (04/2014 - 11/2009)|
|3.||Karp, Daniel D: 4 articles (07/2014 - 07/2009)|
|4.||Langer, Corey J: 3 articles (07/2014 - 11/2009)|
|5.||de Bono, Johann S: 3 articles (04/2014 - 02/2010)|
|6.||Hixon, Mary L: 3 articles (12/2011 - 11/2009)|
|7.||Haluska, Paul: 3 articles (03/2010 - 11/2009)|
|8.||Novello, S: 2 articles (03/2015 - 01/2011)|
|9.||Green, S: 2 articles (03/2015 - 01/2011)|
|10.||Shen, Hongchang: 2 articles (01/2015 - 01/2014)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/01/2011 - "One recent phase III trial of the IGF-1R inhibitor figitumumab in patients with non-small-cell lung cancer was discontinued after an interim analysis showed no survival improvement. "
07/01/2014 - "Our multicenter, randomized, phase III study compared figitumumab plus chemotherapy with chemotherapy alone as first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC). "
03/01/2011 - "Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer."
01/01/2013 - "Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab in non-small cell lung cancer (NSCLC) patients have been discontinued owing to lack of survival benefit. "
01/04/2011 - "Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. "
|2.||Sarcoma (Soft Tissue Sarcoma)
02/01/2010 - "Between January, 2006, and August, 2008, patients with refractory, advanced sarcomas received figitumumab (20 mg/kg) in two single-stage expansion cohorts within a solid-tumour phase 1 trial. "
02/01/2010 - "Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study."
12/01/2011 - "Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma."
02/15/2011 - "Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors."
|3.||Lung Neoplasms (Lung Cancer)
02/01/2015 - "The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer."
03/01/2015 - "This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (NSCLC). "
03/01/2015 - "Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer."
09/15/2010 - "A total of 216 tumor samples were investigated, of which 165 consisted of retrospective analyses of banked tissue and an additional 51 were from patients enrolled in a phase II study of figitumumab, a monoclonal antibody against IGF-IR, in stage IIIb/IV NSCLC. "
04/01/2010 - "Initial pharmacodynamic studies suggested that IGF-IR overexpression and increased bioactivity of IGFs constitute independent mechanisms of tumor sensitivity to figitumumab. "
08/01/2012 - "Tumor biopsies and plasma samples were collected before and after figitumumab administration to monitor the molecular response. "
01/01/2012 - "Out of 17 cancer cell lines, figitumumab effectively inhibited the growth of three cell lines (SNU719, HepG2, and SNU368), decreased p-AKT and p-STAT3 levels, and induced G 1 arrest in a dose-dependent manner. "
08/01/2010 - "The anti-IGF-1 receptor monoclonal antibody, figitumumab, has been developed as an anti-cancer therapeutic. "
|5.||Prostatic Neoplasms (Prostate Cancer)
06/15/2012 - "This study evaluated biologic and clinical effects of figitumumab, a fully human monoclonal IGF-IR antibody, in patients with localized prostate cancer. "
06/15/2012 - "A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer."
06/15/2012 - "Figitumumab is biologically active in prostate cancer. "
04/01/2014 - "Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer."
04/01/2014 - "Figitumumab is a human IgG2 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), with antitumor activity in prostate cancer. "
|2.||erlotinib (CP 358,774)
|7.||sorafenib (BAY 43-9006)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)